| Name | Title | Contact Details |
|---|
Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
Genelabs Technologies, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Semler Research Center Pvt. Ltd. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Icon Genetics is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alfa Wassermann, Inc. is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.